Source: Bone Future; Editor: Sophia
Reprint Requirements: You can directly republish, but please credit the source at the beginning of the article.
April 8, 2024Medical Technology Company Onkos SurgicalRepresents, itsAntibacterial Coated Orthopedic ImplantsReceived FDA De Novo approval.According to the press release, bacterial contamination of permanent implants can have devastating effects, particularly in orthopedic oncology and revision arthroplasty.
After extensive research, it was found thatOnkosImplantThe coating has a bactericidal effect.A kill rate of up to 99.999%.
# OrthopedicsImplant Contamination
Bacterial contamination of orthopedic implants is an increasingly severe clinical challenge, burdening healthcare systems and potentially leading to fatal complications for patients.
Antibacterial Coatings on Orthopedic ImplantsCurrently, there is no highly effective method to address this multifactorial issue.Therefore, Onkos Surgical's recent FDA approval marks a significant advancement, offering another option to reduce localized bacterial contamination around implants.# Core Products of Onkos SurgicalJTS Expandable Prosthesis:An adjustable and extendable implant primarily for pediatric patients with bone cancer, supported by substantial clinical evidence.
By applying magnetic technology, the implant can be extended non-invasively to accommodate the patient's natural growth curve, allowing young patients who have lost bone mass due to cancer to maintain equal limb length.Suitable for children who need to undergo bone tumor surgery.
Received FDA 510(k) approval for non-invasive limb lengthening in pediatric patients;Aimed at growing together with pediatric patients and ultimately accompanying them into adult life;Helps reduce the risk of complications associated with limb-lengthening surgery in pediatric cancer patients;My3D®Personalized Solutions:A 3D printing solution for patients that helps protect their native joints or reconstruct the pelvis.
ELEOS™ Limb Salvage Solution:By means of 3D printing, BioGrip technology, and a patented suture hole design, it helps address issues of soft tissue attachment and aseptic loosening.
Onkos Surgical, Inc. was founded in 2015 and is headquartered in Parsippany, New Jersey, USA. The company focuses on orthopedic oncology research and complex orthopedic surgeries, providing oncologists with new technologies and solutions in an attempt to penetrate the orthopedic medical device market dominated by industry giants such as Stryker and Zimmer Biomet.Onkos Surgical has been committed to addressing the issue of loosening connections between implants and the body. The company's limb salvage system is designed to support bone growth in bone cancer survivors and other complex limb salvage cases. It functions by improving contact between bone implants and the patient’s body, reducing the risk of aseptic loosening, and enhancing the postoperative healing process.In 2022, Onkos Surgical signed the final agreement to acquire Stryker's adolescent tumor system.StrykerThe Onkos Surgical system allows for non-invasive lengthening of implants post-surgery over time in a clinical setting.Three days after acquiring Stryker's adolescent tumor system, Onkos Surgical announced the submission of an amendment confirming the sale of $26.5 million (approximately 178 million RMB) in equity.
Orthopedic Communication Community
Innovative Orthopedic Medical DevicesInternational Orthopedic EnterprisesStryker｜Johnson & Johnson|Zimmer Biomet｜Medtronic | Smith+Nephew｜Enovis｜NuVasive | Globus Medical｜Orthofix｜CONMED
Chinese Orthopedic EnterprisesChunli Medical｜Sanyou Medical｜WEGO Orthopaedics｜Dabo Medical | Kailite Medical｜Aojing Medical｜Haohai BioScience｜AK Medical
